First Study of Intravenous BPC-157 in Humans Shows No Side Effects in Two Patients

IRB-approved pilot safety study. Two participants had baseline blood work and vital signs recorded, then received 10 mg BPC-157 in 250 cc saline IV over one hour on day 1, followed by 20 mg on day 2. Fasting blood work and vitals were repeated on days 2 and 3. Participants were questioned about side effects at each visit.

BPC-157 is one of the most widely discussed peptides in the wellness and biohacking community, yet virtually all published research has been in animals. The near-complete absence of human data has been the elephant in the room. This tiny pilot study from Dr. Edwin Lee — one of very few researchers publishing human BPC-157 data — provides the first formal safety assessment of intravenous administration. While far too small to be definitive, it's a step toward filling the massive evidence gap between animal studies and widespread human use.

BPC-157 has an enormous gap between its animal research base (hundreds of studies showing healing, anti-inflammatory, and protective effects) and its human evidence (almost none). This pilot study, while tiny, represents a meaningful step because it's IRB-approved, formally published, and specifically tests the safety of intravenous administration — the most aggressive route. Dr. Lee's group is essentially the only team publishing human BPC-157 data, making each study significant by default in a field starving for human evidence.

Extremely small sample (n=2) — essentially an anecdotal safety observation, not a powered study. Both participants had prior IV BPC-157 exposure, so truly naïve reactions weren't captured. Only three days of monitoring — no long-term safety data. Published in an alternative medicine journal, not a high-impact clinical journal. No control group. The doses used may not reflect typical clinical applications.